METHIMAZOLE- methimazole tablet AvKARE

Methimazole Tablets, USP Rx only

Rx only


DESCRIPTION

Methimazole, USP (1-methylimidazole-2-thiol) is a white, crystalline substance that is freely soluble in water. It differs chemically from the drugs of the thiouracil series primarily because it has a 5- instead of a 6-membered ring.

Methimazole tablet, USP contains 5 or 10 mg methimazole, an orally administered antithyroid drug.

Each tablet also contains lactose monohydrate, magnesium stearate, potato starch and talc.

The molecular weight is 114.17, and the molecular formula is C $_4$ H $_6$ N $_2$ S. The structural formula is as follows:



CLINICAL PHARMACOLOGY

Methimazole inhibits the synthesis of thyroid hormones and thus is effective in the treatment of hyperthyroidism. The drug does not inactivate existing thyroxine and triiodothyronine that are stored in the thyroid or circulating in the blood nor does it interfere with the effectiveness of thyroid hormones given by mouth or by injection.

Methimazole is readily absorbed in the gastrointestinal tract, metabolized in the liver, and excreted in the urine.

INDICATIONS AND USAGE

Methimazole tablets are indicated:

- In patients with Graves' disease with hyperthyroidism or toxic multinodular goiter for whom surgery or radioactive iodine therapy is not an appropriate treatment option.
- To ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or

CONTRAINDICATIONS

Methimazole tablets are contraindicated in the presence of hypersensitivity to the drug or any of the other product components.

WARNINGS

First Trimester Use of Methimazole and Congenital Malformations

Methimazole crosses the placental membranes and can cause fetal harm, when administered in the first trimester of pregnancy. Rare instances of congenital defects, including aplasia cutis, craniofacial malformations (facial dysmorphism; choanal atresia), gastrointestinal malformations (esophageal atresia with or without tracheoesophageal fistula), omphalocele and abnormalities of the omphalomesenteric duct have occurred in infants born to mothers who received methimazole in the first trimester of pregnancy. If methimazole is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be warned of the potential hazard to the fetus.

Because of the risk for congenital malformations associated with use of methimazole in the first trimester of pregnancy, it may be appropriate to use other agents in pregnant women requiring treatment for hyperthyroidism. If methimazole is used, the lowest possible dose to control the maternal disease should be given.

Agranulocytosis

Agranulocytosis is a potentially life-threatening adverse reaction of methimazole therapy. Patients should be instructed to immediately report to their physicians any symptoms suggestive of agranulocytosis, such as fever or sore throat. Leukopenia, thrombocytopenia, and aplastic anemia (pancytopenia) may also occur. The drug should be discontinued in the presence of agranulocytosis or aplastic anemia (pancytopenia), and the patient's bone marrow indices should be monitored.

Liver Toxicity

Although there have been reports of hepatotoxicity (including acute liver failure) associated with methimazole, the risk of hepatotoxicity appears to be less with methimazole than with propylthiouracil, especially in the pediatric population. Symptoms suggestive of hepatic dysfunction (anorexia, pruritus, right upper quadrant pain, etc.) should prompt evaluation of liver function (bilirubin, alkaline phosphatase) and hepatocellular integrity (ALT, AST). Drug treatment should be discontinued promptly in the event of clinically significant evidence of liver abnormality including hepatic transaminase values exceeding 3 times the upper limit of normal.

Hypothyroidism

Methimazole can cause hypothyroidism necessitating routine monitoring of TSH and free T4 levels with adjustments in dosing to maintain a euthyroid state. Because the drug readily crosses placental membranes, methimazole can cause fetal goiter and cretinism when administered to a pregnant woman. For this reason, it is important that a sufficient, but not excessive, dose be given during pregnancy [see PRECAUTIONS, Pregnancy] .

Vasculitis

Cases of vasculitis resulting in severe complications have been reported in patients receiving methimazole therapy. These cases of vasculitis include: leukocytoclastic cutaneous vasculitis, acute kidney injury and glomerulonephritis, alveolar/pulmonary hemorrhage, CNS vasculitis, and neuropathy. Most cases were associated with anti-neutrophilic cytoplasmic antibodies (ANCA)-positive vasculitis. In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. If vasculitis is suspected, discontinue therapy and initiate appropriate intervention.

PRECAUTIONS

General

Patients who receive methimazole should be under close surveillance and should be cautioned to report immediately any evidence of illness, particularly sore throat, skin eruptions, fever, headache, or general malaise. In such cases, white-blood-cell and differential counts should be obtained to determine whether agranulocytosis has developed. Particular care should be exercised with patients who are receiving additional drugs known to cause agranulocytosis.

Information for Patients

Patients should be advised that if they become pregnant or intend to become pregnant while taking an antithyroid drug, they should contact their physician immediately about their therapy.

Inform patients that cases of vasculitis resulting in severe complications have occurred with methimazole tablets. Inform patients to promptly report symptoms that may be associated with vasculitis including new rash, hematuria or decreased urine output, dyspnea or hemoptysis [see WARNINGSand ADVERSE REACTIONS].

Laboratory Tests

Because methimazole may cause hypoprothrombinemia and bleeding, prothrombin time should be monitored during therapy with the drug, especially before surgical procedures. Thyroid function tests should be monitored periodically during therapy. Once clinical evidence of hyperthyroidism has resolved, the finding of a rising serum TSH indicates that a lower maintenance dose of methimazole should be employed.

Drug Interactions

Anticoagulants (oral)

Due to potential inhibition of vitamin K activity by methimazole, the activity of oral anticoagulants (e.g., warfarin) may be increased; additional monitoring of PT/INR should be considered, especially before surgical procedures.

β -adrenergic blocking agents

Hyperthyroidism may cause an increased clearance of beta blockers with a high extraction ratio. A dose reduction of beta-adrenergic blockers may be needed when a hyperthyroid patient becomes euthyroid.

Digitalis glycosides

Serum digitalis levels may be increased when hyperthyroid patients on a stable digitalis glycoside regimen become euthyroid; a reduced dosage of digitalis glycosides may be needed.

Theophylline

Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; a reduced dose of theophylline may be needed.

Carcinogenesis, Mutagenesis, Impairment of Fertility

In a 2-year study, rats were given methimazole at doses of 0.5, 3, and 18 mg/kg/day. These doses were 0.3, 2, and 12 times the 15 mg/day maximum human maintenance dose (when calculated on the basis of surface area). Thyroid hyperplasia, adenoma, and carcinoma developed in rats at the two higher doses. The clinical significance of these findings is unclear.

Pregnancy

[See WARNINGS.]

If methimazole is used during the first trimester of pregnancy or if the patient becomes pregnant while taking this drug, the patient should be warned of the potential hazard to the fetus.

In pregnant women with untreated or inadequately treated Graves' disease, there is an increased risk of adverse events of maternal heart failure, spontaneous abortion, preterm birth, stillbirth and fetal or neonatal hyperthyroidism.

Because methimazole crosses placental membranes and can induce goiter and cretinism in the developing fetus, hyperthyroidism should be closely monitored in pregnant women and treatment adjusted such that a sufficient, but not excessive, dose be given during pregnancy. In many pregnant women, the thyroid dysfunction diminishes as the pregnancy proceeds; consequently, a reduction of dosage may be possible. In some instances, anti-thyroid therapy can be discontinued several weeks or months before delivery.

Due to the rare occurrence of congenital malformations associated with methimazole use, it may be appropriate to use an alternative anti-thyroid medication in pregnant women requiring treatment for hyperthyroidism, particularly in the first trimester of pregnancy during organogenesis.

Given the potential maternal adverse effects of propylthiouracil (e.g., hepatotoxicity), it may be preferable to switch from propylthiouracil to methimazole for the second and third trimesters.

Nursing Mothers

Methimazole is present in breast milk. However, several studies found no effect on clinical status in nursing infants of mothers taking methimazole. A long-term study of 139 thyrotoxic lactating mothers and their infants failed to demonstrate toxicity in infants who are nursed by mothers receiving treatment with methimazole. Monitor thyroid function at frequent (weekly or biweekly) intervals.

Pediatric Use

Because of post-marketing reports of severe liver injury in pediatric patients treated with propylthiouracil, methimazole is the preferred choice when an anti-thyroid drug is required for a pediatric patient [see DOSAGE AND ADMINISTRATION].

ADVERSE REACTIONS

Major adverse reactions (which occur with much less frequency than the minor adverse reactions) include inhibition of myelopoieses (agranulocytosis, granulocytopenia, thrombocytopenia, and aplastic anemia), drug fever, a lupus-like syndrome, insulin autoimmune syndrome (which can result in hypoglycemic coma), hepatitis (jaundice may persist for several weeks after discontinuation of the drug), periarteritis, and hypoprothrombinemia. Nephritis occurs very rarely. There have been postmarketing case reports of acute pancreatitis.

There are reports of a vasculitis, often associated with the presence of antineutrophilic cytoplasmic antibodies (ANCA), resulting in severe complications [see WARNINGS].

Minor adverse reactions include skin rash, urticaria, nausea, vomiting, epigastric distress, arthralgia, paresthesia, loss of taste, abnormal loss of hair, myalgia, headache, pruritus, drowsiness, neuritis, edema, vertigo, skin pigmentation, jaundice, sialadenopathy, and lymphadenopathy.

To report SUSPECTED ADVERSE REACTIONS, contact AvKARE at 1-855-361-3993; email drugsafety@avkare.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

OVERDOSAGE

Signs and Symptoms

Symptoms may include nausea, vomiting, epigastric distress, headache, fever, joint pain, pruritus, and edema. Aplastic anemia (pancytopenia) or agranulocytosis may be manifested in hours to days. Less frequent events are hepatitis, nephrotic syndrome, exfoliative dermatitis, neuropathies, and CNS stimulation or depression. No information is available on the median lethal dose of the drug or the concentration of methimazole in biologic fluids associated with toxicity and/or death.

Treatment

To obtain up-to-date information about the treatment of overdose, a good resource is your certified Regional Poison Control Center. In managing overdosage, consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics in the patient.

In the event of an overdose, appropriate supportive treatment should be initiated as dictated by the patient's medical status.

DOSAGE AND ADMINISTRATION

Methimazole tablets are administered orally. The total daily dosage is usually given in 3 divided doses at approximately 8-hour intervals.

Adult

The initial daily dosage is 15 mg for mild hyperthyroidism, 30 to 40 mg for moderately severe hyperthyroidism, and 60 mg for severe hyperthyroidism, divided into 3 doses at 8-hour intervals. The maintenance dosage is 5 to 15 mg daily.

Pediatric

Initially, the daily dosage is 0.4 mg/kg of body weight divided into 3 doses and given at 8-hour intervals. The maintenance dosage is approximately ½ of the initial dose.

HOW SUPPLIED

Methimazole tablets, USP 5 mg are supplied as white, round, flat-faced, beveled-edged tablets with "VM" on one side and scored on the other.

They are available in:

Bottles of 100, NDC 73190-029-01

Methimazole tablets, USP 10 mg are supplied as white, round, flat-faced, beveled-edged tablets with "XM" on one side and scored on the other. They are available in:

Bottles of 100, NDC 73190-030-01

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

Dispense in a tight, light-resistant container.

Manufactured for: AvKARE Pulaski, TN 38478 Mfg. Rev. 12/23 AV Rev. 04/25 (M)

PRINCIPAL DISPLAY PANEL - 5 mg Tablet Bottle Label



PRINCIPAL DISPLAY PANEL - 10 mg Tablet Bottle Label



METHIMAZOLE methimazole tablet					
Product Information					
Product Type	HUMAN PRESCRIPTION DRUG	ltem Code (Source)	NDC:73 6072)	3190-029(N	IDC:0832-
Route of Administration	ORAL				
Active Ingredient/Active	e Moiety				
Ingi	redient Name		Basis of St	trength	Strength
METHIMAZOLE (UNII: 554Z48XN	5E) (METHIMAZ OLE - UNII:554	4Z48XN5E)	METHIMAZ OLE		5 mg
Inactive Ingredients					
	Ingredient Name			Str	ength
LACTOSE MONOHYDRATE (UNI	: EWQ57Q8I5X)				
MAGNESIUM STEARATE (UNII: 7	0097M6I30)				
	AH3T)				
STARCH, POTATO (UNII: 810895)					

Pr	oduct Char	acteristics							
Co	lor	white			Sc	ore		2	2 pieces
Sha	аре	ROUND (flat-fac	ed, beveled-edged)		Siz	ze		7	'mm
Fla	vor				Im	print C	Code	V	/M
Со	ntains								
Pa	ckaging								
#	Item Code	Pa	ckage Description		Market D	ting St Date	tart		ting End Date
	NDC:73190-029- 01	100 in 1 BOTT Product	'LE; Type 0: Not a Combinati	on 04	4/24/2025	5			
		I							
	arketing			-					
	Marketing Category	Applica	tion Number or Monog Citation	raph	Mark	eting : Date	Start		eting End Date
ANE	AC	ANDA04054	7		04/24/20	025			
Pr Pro	thimazole tab roduct Infor oduct Type	rmation	HUMAN PRESCRIPTION DRUG	ltem ((Sour			NDC:73 6073)	190-030(N	IDC:0832-
Pro Pro Ro Ac	roduct Infor oduct Type oute of Admin	mation istration ient/Active Ingre	DRUG ORAL	(Sour	ce)	Basis	6073) 5 of St	190-030(N rength	
Pro Pro Ro Ac	roduct Infor oduct Type oute of Admin ctive Ingred	mation istration ient/Active Ingre	DRUG ORAL Moiety edient Name	(Sour	ce)		6073) 5 of St		Strengt
Pro Pro Ro Ac	roduct Infor oduct Type oute of Admin	mation istration ient/Active Ingre	DRUG ORAL Moiety edient Name E) (METHIMAZ OLE - UNII:5542	(Sour	ce)		6073) 5 of St	rength	Strengt 10 mg
Pro Ro Ac ME	roduct Infor oduct Type oute of Admin tive Ingred THIMAZOLE (U active Ingre	mation istration ient/Active ingre NII: 554Z48XN51 edients	DRUG ORAL Moiety edient Name E) (METHIMAZ OLE - UNII:5542 Ingredient Name	(Sour	ce)		6073) 5 of St	rength	Strengt
Pro Ro Ac ME	roduct Infor oduct Type oute of Admin tive Ingred THIMAZOLE (U active Ingre	mation istration ient/Active ient/Active Ingre NII: 554Z48XN5I edients	DRUG ORAL Moiety edient Name E) (METHIMAZ OLE - UNII:5542 Ingredient Name EWQ57Q8I5X)	(Sour	ce)		6073) 5 of St	rength	Strengt 10 mg
Pro Ro Ac ME	roduct Infor oduct Type oute of Admin tive Ingred THIMAZOLE (U active Ingre	rmation istration ient/Active ingre NII: 554Z48XN51 edients iyDRATE (UNII: ARATE (UNII: 70)	DRUG ORAL Moiety edient Name E) (METHIMAZ OLE - UNII:5542 Ingredient Name EWQ57Q8I5X) 097M6I30)	(Sour	ce)		6073) 5 of St	rength	Strengt 10 mg
Pro Ro Ac ME	roduct Infor oduct Type oute of Admin tive Ingred THIMAZOLE (U active Ingre	mation istration ient/Active ient/Active ingre NII: 554Z48XN5I edients ivDRATE (UNII: ARATE (UNII: 70 (UNII: 810895A	DRUG ORAL Moiety edient Name E) (METHIMAZ OLE - UNII:5542 Ingredient Name EWQ57Q8I5X) 097M6I30)	(Sour	ce)		6073) 5 of St	rength	Strengt 10 mg
Pro Ro Ac ME Ina LAC MA	roduct Infor oduct Type oute of Admin tive Ingred THIMAZOLE (U active Ingre CTOSE MONOH GNESIUM STEA	mation istration ient/Active Ingre NII: 554Z48XN5I edients IYDRATE (UNII: ARATE (UNII: 70 (UNII: 81089SAF 4R1U)	DRUG ORAL Moiety edient Name E) (METHIMAZ OLE - UNII:5542 Ingredient Name EWQ57Q8I5X) 097M6I30)	(Sour	ce)		6073) 5 of St	rength	Strengt 10 mg
Pro Ro Ac ME Ina LAC MA ST/ TAL	roduct Infor oduct Type oute of Admin tive Ingred THIMAZOLE (U active Ingre CTOSE MONOH GRESIUM STE/ ARCH, POTATO LC (UNII: 7SEV7)	mation istration ient/Active Ingre NII: 554Z48XN5I edients IYDRATE (UNII: ARATE (UNII: 70 (UNII: 81089SAF 4R1U)	DRUG ORAL Moiety edient Name E) (METHIMAZ OLE - UNII:5542 Ingredient Name EWQ57Q8I5X) 097M6I30)	(Sour	ce)		6073) 5 of St	rength Str	Strengt 10 mg
Pro Ro Ac ME [*] Ina LAC MA ST/ TAL	roduct Infor oduct Type oute of Admin tive Ingred THIMAZOLE (U active Ingre CTOSE MONOH GNESIUM STEA ARCH, POTATO LC (UNII: 7SEV7)	rmation istration ient/Active Ingre NII: 554Z48XN51 edients PDRATE (UNII: ARATE (UNII: 70 (UNII: 81089SAF 4R1U) acteristics white	DRUG ORAL Moiety edient Name E) (METHIMAZ OLE - UNII:5542 Ingredient Name EWQ57Q8I5X) 097M6I30)	(Sour	ce)	ore	6073) 5 of St	rength Str	Strengt 10 mg
Pro Ro Ac ME Ina LAC MA STA TAL Pro Col Sha	roduct Infor oduct Type oute of Admin tive Ingred THIMAZOLE (U active Ingre CTOSE MONOH GRESIUM STEA ARCH, POTATO LC (UNII: 7SEV7)	rmation istration ient/Active Ingre NII: 554Z48XN51 edients PDRATE (UNII: ARATE (UNII: 70 (UNII: 81089SAF 4R1U) acteristics white	DRUG ORAL Moiety edient Name E) (METHIMAZ OLE - UNII:5542 Ingredient Name EWQ57Q8I5X) 097M6I30) 13T)	(Sour	E) Sc Sc Siz	ore	6073) s of St IAZ OLE	rength Str	Strengt 10 mg ength

Pa	ackaging			
#	ltem Code	Package Description	Marketing Start Date	Marketing End Date
		100 in 1 BOTTLE; Type 0: Not a Combination Product	04/24/2025	
	01	Product		
	-	Information		
	-		Marketing Start Date	Marketing End Date

Labeler - AVKARE (796560394)

Revised: 4/2025

AvKARE